Skip to content
lifestyle.pluralist.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Knight Therapeutics
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
March 17, 2026
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2025 Results Conference Call
March 12, 2026
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
February 18, 2026
←
Previous Page
1
2